Inhibition of Lapatinib-induced Kinome Reprogramming in ERBB2-positive Breast Cancer by Targeting BET Family Bromodomains

Therapeutics such as lapatinib that target ERBB2 often provide initial clinical benefit but resistance frequently develops. Adaptive responses leading to lapatinib resistance involve reprogramming of the kinome through reactivation of ERBB2/ERBB3 signaling and transcriptional upregulation and activa...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cell Rep
Autors principals: Stuhlmiller, Timothy J., Miller, Samantha M., Zawistowski, Jon S., Nakamura, Kazuhiro, Beltran, Adriana S., Duncan, James S., Angus, Steven P., Collins, Kyla A. L., Granger, Deborah A., Reuther, Rachel A., Graves, Lee M., Gomez, Shawn M., Kuan, Pei-Fen, Parker, Joel S., Chen, Xin, Sciaky, Noah, Carey, Lisa A., Earp, H. Shelton, Jin, Jian, Johnson, Gary L.
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4408261/
https://ncbi.nlm.nih.gov/pubmed/25865888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.celrep.2015.03.037
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars